-
Circle Aug. 12-15, 2004, on the calendar for the Minority Womens Health Summit sponsored by the Office of Public Health and Science, Office on Womens Health. The summit, Women of Color, Taking Action for a Healthier Life: Progress, Partnerships and Possibilities, will build upon the first national conference held in 1997.
-
Check the following web sites to get teen-friendly information to share with your adolescent patients.
-
Plan now to attend the HIV Prevention Leadership Summit, scheduled for June 16-19, 2004, at the Georgia World Congress Center in Atlanta.
-
The Today contraceptive sponge awaits the results of a Food and Drug Administration (FDA) review to return to the shelves in the United States. After being approved by the FDA in 1983, the sponge achieved considerable popularity before production was discontinued in 1995. Since then, Allendale (NJ) Pharmaceuticals has purchased rights to the Today sponge and has been working to bring the product back to the United States.
-
Women who initially were diagnosed with Stage IA disease and who had serous borderline tumors or underwent cystectomy appeared to derive the most benefit from restaging surgery. Nonetheless, the indications for restaging surgery remain controversial, as no difference in recurrence rate was observed between women who underwent restaging and those who did not.
-
In this special feature, up-to-date information will be provided regarding the risks and benefits of various diagnostic methods available today for patients of advanced maternal age (AMA).
-
Positive Alendronate Data in Osteoporosis; NSAIDs For Myocardial Infarction; Four-Hour Window for CAP Patients; FDA Actions.
-
-
Strides are being made when it comes to herpes. New treatments are emerging, and an advanced clinical trial of a potential herpes vaccine now is under way.
-
The decision to move the levonorgestrel emergency contraceptive pill Plan B (Barr Laboratories, Pomona, NY) to over-the-counter status has been delayed by the Food and Drug Administration.